About Us

About us

TargED is a spin-off of the University Medical Center Utrecht, founded in July 2020 by Coen Maas, Steven de Maat, Marc van Moorsel and Kristof Vercruysse. Coen, Steven and Marc hold a PhD in the field of thrombosis and hemostasis from Department of Clinical Chemistry and Haematology at UMC Utrecht. Kristof has more than 20 years of experience in bringing biopharmaceutical compounds from pre-clinical proof of concept to market, most notably, Caplacizumab for Thrombotic Thrombocytopenic Purpura at Ablynx between 2007 and 2013. Since 2020, TargED raised more than €45 million of funding  and expanded the team to >15 people.

TargED’s lead compound is TGD001. In preclinical models, it has shown effective thrombolysis for various forms of thrombosis. It is currently preclinically validated in two thrombotic indications: Immune Thrombotic Thrombocytopenic Purpura (iTTP – an orphan indication) and Acute Ischemic Stroke (AIS). The ambition is to accelerate thrombolysis in all forms of thrombosis, irrespective of the thrombus composition.

In 2022, TargED raised €45M of funding from an internal syndicate of VC investors and a loan from the Dutch government. TargED has a worldwide, exclusive license on the IP, covering TGD001 and variant fusion proteins.

Full team

“The ambition is to accelerate thrombolysis in all forms of thrombosis”